If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Verzenio ® (abemaciclib) tablets
50mg, 100mg, 150mg, 200mgThis information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Abemaciclib is indicated
in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with HR+, HER2- advanced or MBC
in combination with fulvestrant for the treatment of women with HR+, HER2- advanced or MBC with disease progression following ET, and
as monotherapy for the treatment of adult patients with HR+, HER2- advanced or MBC with disease progression following ET and prior chemotherapy regimens in the metastatic setting.1
Mechanism of Action
Abemaciclib is an inhibitor of CDK4 and CDK6. These kinases are activated upon binding to D-cyclins. In ER+ breast cancer cell lines, cyclin D1 and CDK4/6 promote phosphorylation of the Rb, cell cycle progression, and cell proliferation. In vitro, continuous exposure to abemaciclib inhibited Rb phosphorylation and blocked progression from G1 into S phase of the cell cycle, resulting in senescence and apoptosis. In breast cancer xenograft models, abemaciclib dosed daily without interruption as a single agent or in combination with antiestrogens resulted in reduction of tumor size.1
Enclosed Prescribing Information
VERZENIO® (abemaciclib) tablets, for oral use, Lilly
1. Verzenio [package insert]. Indianapolis, IN: Eli Lilly and Company; 2018.
Glossary
CDK = cyclin-dependent kinase
ER+ = estrogen receptor-positive
ET = endocrine therapy
HER2- = human epidermal growth factor receptor 2-negative
HR+ = hormone receptor-positive
MBC = metastatic breast cancer
Rb = retinoblastoma protein
Date of Last Review: October 11, 2018
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon - Fri, 9am - 7pm EST